Abstract #3315

Temporal changes in cardiac contractility, perfusion and infarct size after human cardiomyocyte transplantation to the infarcted heart of non-human primates.

Anna V Naumova^1,2,3, William S Kerwin¹, Yen-Wen Liu^2,3,4,5, Billy Chen^2,3,6, Xiulan Yang^2,3,5, Hiroshi Tsuchida ^2,3,5, R. Scott Thies^2,3,5, and Charles E Murry^2,3,5,6

¹Radiology, University of Washington, Seattle, WA, United States, ²Center for Cardiovascular Biology, University of Washington, Seattle, WA, United States, ³Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, WA, United States, ⁴Department of Internal Medicine, National Cheng Kung University, Tainan, Taiwan, ⁵Pathology, University of Washington, Seattle, WA, United States, ⁶Medicine/Cardiology, University of Washington, Seattle, WA, United States

This study demonstrates structural and functional benefits of human embryonic stem cell derived cardiomyocyte engraftment to the infarcted heart of nonhuman primates. Those benefits were manifested in improved global and regional left ventricle contractile function, improved myocardial perfusion, decrease in infarct size and partial regeneration of the scarred myocardium. The benefit from human cardiomyocyte therapy was durable with the potential for further improvement in function between 1 and 3 months. The functional recovery was larger than were observed previously on small animal models of myocardial infarction, which might be due to the greater physiological match between human and macaque species.

This abstract and the presentation materials are available to members only; a login is required.

Join Here